Sygnature Discovery
The drug discovery and preclinical services company has added four new hires to its senior management team to boost its drug metabolism and pharmacokinetics (DMPK) capabilities.
Sygnature last month made two appointments, with Dr. Allan Jordan and Louisa Jordison joining the organization to support the company’s growth trajectory.
Dr. Stuart Best joins from RedX Pharma as the associate director of DMPK. In this role he will manage and supervise growth of the company’s Alderley Park-based DMPK team. The company opened the Alderley Park location in 2018 in response to an increasing demand for outsourced preclinical research services.
“I look forward to providing senior leadership for the Alderley Park base team and with the team aim to build a center of excellence for bioanalysis and in vivo PK to complement and support the broad DMPK offering from the department at Nottingham laboratories,” Best told us.
Joining him at the Alderley Park location is Dr. Wqrren Keene, who is transferring from the company’s Nottingham headquarters to support the management of the facility.